Amer Zeidan: A watershed moment for Myelodysplastic syndromes

Amer Zeidan, shared a post on LinkedIn:

“A watershed moment for Myelodysplastic syndromes with the first approval of a targeted therapy, the first approval in relapsed/refractory setting, & opens the door widely for precision medicine in MDS. FDA approves ivosidenib for MDS”

For the article click here.
Source: Amer Zeidan/LinkedIn

Amer Zeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid Malignancies DART (Disease Aligned Research Team), and the director of Continuing Medical Education (CME) at the Hematology division and chairs the Protocol Review Committee (PRC) at Yale Cancer Center. Dr. Zeidan is a well-known leukemia researcher with a special focus on targeted therapies and immunotherapy for myeloid malignancies, and a social media influencer in the field of blood cancer.